Skip to main content

Aligos Therapeutics, Inc.

corporate_fare Company Profile

Aligos Therapeutics, Inc.

ALGS·NASDAQ·Life Sciences·CIK 0001799448

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing new treatments for liver diseases and viral infections. The company focuses on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (such as SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and related infections). Aligos's drug candidate pipeline includes pevifoscorvir sodium (previously ALG-000184) for chronic HBV infection, ALG‑055009 for MASH and obesity, and ALG‑097558 for coronavirus infections, along with preclinical programs. Pevifoscorvir sodium is a Capsid Assembly Modulator (CAM‑E) for chronic HBV infection. Preclinical testing showed enhanced pharmacologic properties compared to competitor CAM‑E drugs and greater HBV DNA suppression than standard nucleos(t)ide analogs (NAs). A multi‑part Phase 1 clinical trial, spanning up to 96 weeks, demonstrated multi-log 10 reductions in viral antigens. ALG‑055009 is a thyroid hormone receptor beta (THR‑β) agonist for MASH and obesity. Data to date suggest enhanced pharmacologic properties compared to competitor THR‑β agonists. Phase 2a topline data showed that ALG‑055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12, measured by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF), in subjects with presumed MASH. Recent nonclinical data indicate synergistic fat mass loss when combined with incretin receptor agonists in diet-induced obese (DIO) mice. ALG‑097558 is a small molecule coronavirus 3CL protease inhibitor (PI). It is at least 3‑fold more potent in cell‑based assays of coronavirus infection than other approved CoV PIs. Based on Phase 1 clinical studies, the company believes it can be dosed twice daily without requiring ritonavir co-dosing.

Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ALGS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ALGS spans 10-Q, 8-K, SCHEDULE 13D, DEFA14A.

Recent high-impact activity:

  • Aligos 10-Q: $31.1M Cash Funds Operations Only Into Q1 2027, Going Concern Flagged
  • Aligos Posts $2.09 Per-Share Q3 Loss as Cash Crunch Looms
  • Aligos Doses First Patient in Phase 1 Trial of Next-Gen HBV Drug ALG-170675
  • Aligos Q2 Loss Narrows to $1.5M on $28M Licensing Revenue, Cash Runway Through Q4
  • Licensing revenue narrows Aligos' Q2 loss, but cash runway shrinks to Q4 2026 — going concern warning stands

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.19M
Net Income
-$24.19M
Diluted EPS
-$2.45
Op. Cash Flow
-$82.5M
Operating Income
-$87.98M
Cash & Equivalents
$18.3M
Debt / Equity
0.00×
Net Margin
-11.07×
Shares Outstanding
6.18M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-092614

Short Interest & Short Volume

20.77 days to cover

FINRA reported short interest of 677,218 shares in ALGS as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 20.8 days to cover at its recent average daily volume. On November 20, 2026, 62.0% of ALGS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)677,218 shares as of October 30, 2026
Change vs prior period▼ 4.3%
Days to cover20.77 at avg daily volume of 32,604
Daily short volume (FINRA facilities)62.0% of 55,281 shares on November 20, 2026
5-day average short volume58.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$1.17 -4.09% today
52-week range · as of 2026-11-06 $1.17 – $13.69
Market cap
$8.6M
Volume
106.8K (1.6× avg)
3-mo avg 68.8K
Live data · 2026-11-21 10:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALGS - Latest Insights

ALGS
Nov 06, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.46
Real-time Price: $1.17 info
Change: -$3.29 (-74%) info
Market Cap: $8.599M info
ALGS
Nov 06, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $1.17 info
Change: -$3.34 (-74%) info
Market Cap: $8.599M info
ALGS
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $1.17 info
Change: -$5.83 (-83%) info
Market Cap: $8.599M info
ALGS
Aug 06, 2026, 8:19 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.52
Real-time Price: $1.17 info
Change: -$3.35 (-74%) info
Market Cap: $8.599M info
ALGS
Aug 06, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.52
Real-time Price: $1.17 info
Change: -$3.35 (-74%) info
Market Cap: $8.599M info
ALGS
Aug 06, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.52
Real-time Price: $1.17 info
Change: -$3.35 (-74%) info
Market Cap: $8.599M info
ALGS
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.90
Real-time Price: $1.17 info
Change: -$5.73 (-83%) info
Market Cap: $8.599M info
ALGS
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.05
Real-time Price: $1.17 info
Change: -$5.88 (-83%) info
Market Cap: $8.599M info
ALGS
Jun 26, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.57
Real-time Price: $1.17 info
Change: -$4.40 (-79%) info
Market Cap: $8.599M info
ALGS
Jun 24, 2026, 4:30 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $5.58
Real-time Price: $1.17 info
Change: -$4.40 (-79%) info
Market Cap: $8.599M info
ALGS
May 27, 2026, 2:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.70
Real-time Price: $1.17 info
Change: -$4.53 (-79%) info
Market Cap: $8.599M info
ALGS
May 07, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.12
Real-time Price: $1.17 info
Change: -$4.95 (-81%) info
Market Cap: $8.599M info
ALGS
May 07, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.12
Real-time Price: $1.17 info
Change: -$4.95 (-81%) info
Market Cap: $8.599M info
ALGS
Apr 29, 2026, 4:33 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $5.90
Real-time Price: $1.17 info
Change: -$4.73 (-80%) info
Market Cap: $8.599M info
ALGS
Apr 29, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $5.97
Real-time Price: $1.17 info
Change: -$4.80 (-80%) info
Market Cap: $8.599M info
ALGS
Apr 21, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.55
Real-time Price: $1.17 info
Change: -$5.38 (-82%) info
Market Cap: $8.599M info
ALGS
Apr 16, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.50
Real-time Price: $1.17 info
Change: -$7.33 (-86%) info
Market Cap: $8.599M info
ALGS
Apr 14, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.53
Real-time Price: $1.17 info
Change: -$7.36 (-86%) info
Market Cap: $8.599M info
ALGS
Mar 05, 2026, 8:08 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $7.20
Real-time Price: $1.17 info
Change: -$6.03 (-84%) info
Market Cap: $8.599M info
ALGS
Mar 05, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.20
Real-time Price: $1.17 info
Change: -$6.03 (-84%) info
Market Cap: $8.599M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets